# EDGAR Filing Document

**Accession Number:** 0002011385
**File Stem:** 0001104659-25-085383
**Filing Date:** 2025-8
**Character Count:** 5751
**Document Hash:** 00cb725b9593233f9b9b3c7edbe4e159
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-085383.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001104659-25-085383

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Catalys Pacific, LLC
- **CENTRAL INDEX KEY:** 0002011385

**ORGANIZATION NAME:**
- **EIN:** 981467359
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-23817
- **FILM NUMBER:** 251277669

**BUSINESS ADDRESS:**
- **STREET 1:** VORT MINAMIAOYAMA III 4F
- **STREET 2:** 8-14, MINAMI-AOYAMA 3-CHOME, MINATO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 107-0062
- **BUSINESS PHONE:** 81-50-1744-2996

**MAIL ADDRESS:**
- **STREET 1:** VORT MINAMIAOYAMA III 4F
- **STREET 2:** 8-14, MINAMI-AOYAMA 3-CHOME, MINATO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 107-0062

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0002011385

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Catalys Pacific, LLC

**Address:** 8-14, Tokyo, M0 107-0062

**Telephone number:** 81-50-1744-2996

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-23817

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | VOTE CATEGORY                                                                 |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| Mineralys Therapeutics, Inc.  | 603170101 | 05/22/2025     | 1a. Election of Class II Director for a three-year term to expire at the 2028 Annual Meeting of stockholders: Glenn P. Sblendorio 1b. Election of Class II Director for a three-year term to expire at the 2028 Annual Meeting of stockholders: Derek DiRocco, Ph.D. 2. Ratify the appointment of Ernst  Young LLP as Mineralys Therapeutics, Inc.'s independent registered public accounting fi rm for the fi scal yearending December 31, 2025.                                                                                                                                                                                                                                                                                                                            | DIRECTOR ELECTIONS; SECTION 14A SAY-ON-PAY VOTES; AUDIT-RELATED               |        8903838 |                0 |  |  |  |  |
| Phathom Pharmaceuticals, Inc. | 71722W107 | 06/03/2025     | 1a: To elect Heidi Kunz to serve as Class III director for a three-year term to expire at the 2028 annual meeting of stockholders. 1b: To elect James Topper, M.D., Ph.D. to serve as Class III director for a three-year term to expire at the 2028 annual meeting of stockholders. 2: To ratify the appointment of Ernst  Young LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 3: To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay"). 4: To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers ("say-on-frequency"). | DIRECTOR ELECTIONS; SECTION 14A SAY-ON-PAY VOTES; AUDIT-RELATED; COMPENSATION |              0 |                0 |  |  |  |  |

## N-PX: Signature Block

**Reporting Person:** Catalys Pacific, LLC

**By (Signature):** Brian Taylor Slingsby

**By (Printed Signature):** Brian Taylor Slingsby

**By (Title):** Managing Director  Chief Compliance Officer

**Date:** 08/27/2025